An Empirical Approach towards the Efficient and Optimal Production of Influenza-Neutralizing Ovine Polyclonal Antibodies Demonstrates That the Novel Adjuvant CoVaccine HT？ Is Functionally Superior to Freund's Adjuvant
Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT？ was compared to Freund’s adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT？ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund’s adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together, these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies specifically for the prevention and treatment of globally significant diseases.
References
[1]
Lynch MJ, Ritter SC, Cannon RD (2010) Successful treatment of South American rattlesnake (Crotalus durissus terrificus) envenomation with Crotalidae polyvalent immune Fab (CroFab). J Med Toxicol 7: 44–46.
[2]
McMillin GA, Owen WE, Lambert TL, De BK, Frank EL, et al. (2002) Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem 48: 1580–1584.
[3]
Redwan el RM, Fahmy A, El Hanafy A, Abd El-Baky N, Sallam SM (2009) Ovine anti-rabies antibody production and evaluation. Comp Immunol Microbiol Infect Dis 32: 9–19.
[4]
Sjostrom L, al-Abdulla IH, Rawat S, Smith DC, Landon J (1994) A comparison of ovine and equine antivenoms. Toxicon 32: 427–433.
[5]
Newcombe C, Newcombe AR (2007) Antibody production: polyclonal-derived biotherapeutics. J Chromatogr B Analyt Technol Biomed Life Sci 848: 2–7.
[6]
O’Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, et al.. (2012) Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice. MBio 3.
[7]
Kourti A, Spanakos G, Politi L, Stavropoulou A, Spanakis N, et al. (2012) Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post-pandemic 2010–2011 season. Int J Antimicrob Agents 40: 72–74.
[8]
Barnhill AE, Brewer MT, Carlson SA (2012) Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components. Antimicrob Agents Chemother.
[9]
Nakagawa Y, Nagai T, Okawara H, Nakashima H, Hisamatsu A, et al.. (2011) Acute hemorrhagic colitis induced by the oral administration of oseltamivir used for influenza A treatment. Endoscopy 43 Suppl 2 UCTN: E261.
[10]
Grant LM, Rockey DC (2012) Drug-induced liver injury. Curr Opin Gastroenterol 28: 198–202.
[11]
Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663–1673.
Luytjes W, Enouf V, Schipper M, Gijzen K, Liu WM, et al. (2012) HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains. Vaccine. 30: 5262–5269.
[14]
McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, et al. (2012) The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 30: 2060–2067.
[15]
Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, et al. (2012) Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine 30: 5009–5018.
[16]
van Ierssel SH, Leven M, Jorens PG (2012) Severe influenza A(H1N1)2009 infection: a single centre experience and review of the literature. Acta Clin Belg 67: 1–6.
[17]
Patria MF, Tenconi R, Esposito S (2012) Efficacy and safety of influenza vaccination in children with asthma. Expert Rev Vaccines 11: 461–468.
[18]
Ye J, Shao H, Perez DR (2012) Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy 4: 175–186.
[19]
Ng WC, Wong V, Muller B, Rawlin G, Brown LE (2010) Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS One 5: e13622.
[20]
Wu JT, Lee CK, Cowling BJ, Yuen KY (2011) Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic. Influenza Other Respi Viruses 5 Suppl 1226–229.
[21]
Cresswell C, Newcombe AR, Davies S, Macpherson I, Nelson P, et al. (2005) Optimal conditions for the papain digestion of polyclonal ovine IgG for the production of bio-therapeutic Fab fragments. Biotechnol Appl Biochem 42: 163–168.
[22]
Newcombe AR, Cresswell C, Davies S, Watson K, Harris G, et al. (2005) Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent A2P. J Chromatogr B Analyt Technol Biomed Life Sci 814: 209–215.
[23]
Chhatre S, Francis R, Newcombe AR, Zhou Y, Titchener-Hooker N, et al. (2008) Global Sensitivity Analysis for the determination of parameter importance in bio-manufacturing processes. Biotechnol Appl Biochem 51: 79–90.
[24]
Leenaars M, Hendriksen CF (2005) Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. ILAR J 46: 269–279.
[25]
Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, et al. (2011) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 19: 209–218.
[26]
Guan J, Wen B, Deng Y, Zhang K, Chen H, et al. (2011) Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J 8: 506.
[27]
Suda T, Kawano M, Nogi Y, Ohno N, Akatsuka T, et al. (2011) The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus. Antiviral Res 91: 252–258.
[28]
Vidard L, Rock KL, Benacerraf B (1992) Heterogeneity in antigen processing by different types of antigen-presenting cells. Effect of cell culture on antigen processing ability. J Immunol 149: 1905–1911.
[29]
Mine Y, Yang M (2007) Epitope characterization of ovalbumin in BALB/c mice using different entry routes. Biochim Biophys Acta 1774: 200–212.
[30]
Buckwalter MR, Albert ML (2009) Orchestration of the immune response by dendritic cells. Curr Biol 19: R355–361.
[31]
Hinkula J, Walther-Jallow L, Lauren A, Makitalo B, Oberg M, et al. (2009) Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells. Vaccine 27: 6424–6431.
[32]
Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, et al. (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225–234.
[33]
Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, et al. (1997) Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156: 199–209.
[34]
Singh M, Srivastava I (2003) Advances in vaccine adjuvants for infectious diseases. Curr HIV Res 1: 309–320.
[35]
Fraser CK, Diener KR, Brown MP, Hayball JD (2007) Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 6: 559–578.
[36]
Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, et al. (2010) A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 84: 7943–7952.
[37]
Cooper HM, Paterson Y (2009) Production of polyclonal antisera. Curr Protoc Neurosci Chapter 5: Unit 5 5.
[38]
Cox JC, Coulter AR (1997) Adjuvants–a classification and review of their modes of action. Vaccine 15: 248–256.
[39]
Ogonuki H, Hashizume S, Takashashi B (1967) Preparation and laboratory tests of oil-adjuvant cholera vaccine. Bull World Health Organ 37: 729–736.
Blom AG, Hilgers LA (2004) Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 23: 743–754.
[42]
de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, et al. (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602–2616.
[43]
Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, et al. (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583–7595.
[44]
Fry A, Shafer A, Conrad S (2011) Supplemented Assay Method for Conducting the Hemagglutination Inhibition Assay for Equine Influenza Antibody. In: Agriculture USDo, editor: Center for Veterinary Biologics.
[45]
Martin-Gomez S, Alvarez-Sanchez MA, Rojo-Vazquez FA (2006) Obtaining hyperimmune anti-Cryptosporidium parvum ovine colostrum. A study of the humoral immune response in immunized sheep. Parasitol Res 98: 119–129.
[46]
Thatte J, Rath S, Bal V (1995) Analysis of immunization route-related variation in the immune response to heat-killed Salmonella typhimurium in mice. Infect Immun 63: 99–103.
[47]
Bodewes R, Geelhoed-Mieras MM, Heldens JG, Glover J, Lambrecht BN, et al. (2009) The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 27: 6833–6839.
[48]
Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, et al. (2011) Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6: e20547.
[49]
Turkstra JA, van der Staay FJ, Stockhofe-Zurwieden N, Woelders H, Meloen RH, et al. (2011) Pharmacological and toxicological assessment of a potential GnRH vaccine in young-adult male pigs. Vaccine 29: 3791–3801.
[50]
Ueno H, Schmitt N, Palucka AK, Banchereau J (2010) Dendritic cells and humoral immunity in humans. Immunol Cell Biol 88: 376–380.
[51]
Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, et al. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29: 497–510.
[52]
Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19: 2666–2672.
[53]
Scibienski RJ (1973) Denaturation of lysozyme by Freund’s complete adjuvant. J Immunol 111: 114–120.
[54]
Committee AWA (2012) Guidelines for the Harvesting of Blood from Livestock for Commercial and Research Purposes. In: Industries DoP, editor.
[55]
Ochsenbein AF, Zinkernagel RM (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21: 624–630.
[56]
Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. (2010) Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins. PLoS Pathog 6: e1000796.
[57]
Santiago FW, Fitzgerald T, Treanor JJ, Topham DJ (2011) Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus. Vaccine 29: 8888–8897.
[58]
Berry JD, Gaudet RG (2011) Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol 28: 489–501.
[59]
Hong DK, Tremoulet AH, Burns JC, Lewis DB (2010) Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 30: 67–69.
